Embramine: Indication, Dosage, Side Effect, Precaution

This information is not country-specific. Please refer to the Myanmar prescribing information.

Generic Medicine Info

Indications and Dosage

Oral
Allergic conditions

Adult: 25-50 mg daily.
Child: Same as adult dose.
Elderly:

Contraindications

Urinary or GI tract obstruction, paralytic ileus. Pregnancy and lactation.

Special Precautions

Patient w/ closed-angle glaucoma, prostate enlargement, heart disease, and epilepsy. Childn.

Adverse Reactions

Headache, sleep disorder, hypotension, loss of appetite, asthma, bone marrow depression, constipation, drowsiness, increased sweating, tingling, shock, swelling, wt gain, urinary hesitancy, urinary retention, CNS depression, dry mouth, thickening of resp secretions, blurred vision, GI upset, tinnitus, vertigo, giddiness, nausea, paraesthesia, bradycardia followed by tachycardia and arrhythmias; paradoxical stimulation in childn.

Patient Counseling Information

May impair ability to drive or operate machinery.

Drug Interactions

Additive anti-muscarinic effect w/ MAOIs, TCAs and atropine. Enhances the CNS depressant effect of barbiturates, sedatives, hypnotics, analgesics and neuroleptics. Masks ototoxicity produced by aminoglycosides.

Food Interaction

Enhances the CNS depressant effect of alcohol.

Action

Description: Embramine selectively binds to but do not activate histamine H₁ receptors, thereby blocking the actions of endogenous histamine.

Storage

Store at room temp.

MIMS Class

Antihistamines & Antiallergics

References

Buckingham R (ed). Embramine Hydrochloride. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 15/04/2016.

Embramine. National Center for Biotechnology Information. PubChem Database. https://pubchem.ncbi.nlm.nih.gov/. Accessed 15/04/2016 .

Mebryl (GlaxoSmithKline). MIMS India. http://www.mims.com/india. Accessed 15/04/2016 .

Disclaimer: This information is independently developed by MIMS based on Embramine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by MIMS.com